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Clinical PerspectiveWhat Is New?In patients with stable coronary heart disease, geographic region, mood, and lifestyle risk factors are strong determinants of self‐reported health.Self‐reported general health is a strong independent predictor of cardiovascular mortality, noncardiovascular mortality, and myocardial infarction.What Are the Clinical Implications?General health should be considered in addition to traditional risk factors when estimating the risk of adverse cardiovascular events.It is possible that interventions that improve general health, either at the individual or general population level, will also lower cardiovascular risk.

Introduction {#jah32465-sec-0009}
============

An important goal of management of patients with stable coronary heart disease (CHD) is to improve physical, mental, and/or social well‐being. Consequently, it is relevant to consider the overall general health of the patient when deciding on a management strategy. Better understanding of the determinants of general health and of how general health may influence the risk of adverse clinical outcomes has the potential to improve clinical decisions.

General health is usually considered to be a patient‐centered measure.[1](#jah32465-bib-0001){ref-type="ref"} It can be assessed by asking patients about their physical, mental, and social functioning and other aspects of quality of life using questionnaires such as the Short Form--36[2](#jah32465-bib-0002){ref-type="ref"} and the EQ‐5D.[3](#jah32465-bib-0003){ref-type="ref"} The simplest assessment of health can be obtained by asking a single question: "How is your overall health?" In large epidemiological studies, the response to this simple question predicted both total and cardiovascular mortality.[4](#jah32465-bib-0004){ref-type="ref"}, [5](#jah32465-bib-0005){ref-type="ref"}, [6](#jah32465-bib-0006){ref-type="ref"} Few studies, however, have evaluated the clinical importance of this simple indicator of overall health in CHD patients.[7](#jah32465-bib-0007){ref-type="ref"}, [8](#jah32465-bib-0008){ref-type="ref"}, [9](#jah32465-bib-0009){ref-type="ref"} In addition, the primary determinants of self‐reported health in patients with stable CHD are uncertain.

The aims of this study were to describe the most important factors associated with self‐reported health and to evaluate its independent association with outcomes in patients with stable CHD who participated in the global STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial.[10](#jah32465-bib-0010){ref-type="ref"}, [11](#jah32465-bib-0011){ref-type="ref"}

Methods {#jah32465-sec-0010}
=======

Study Population {#jah32465-sec-0011}
----------------

The STABILITY trial ([ClinicalTrials.gov](http://www.ClinicalTrials.gov) identifier NCT00799903) was a global outcomes trial designed to determine whether darapladib, a specific inhibitor of lipoprotein‐associated phospholipase A~2~, would reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with chronic CHD.[10](#jah32465-bib-0010){ref-type="ref"} In total, 15 828 participants from 39 countries were randomized. All patients had chronic stable CHD, defined as prior myocardial infarction, prior coronary revascularization, or multivessel CHD confirmed by coronary angiography. In addition, patients had to meet at least one of the following cardiovascular risk criteria: age ≥60 years; diabetes mellitus requiring pharmacotherapy; high‐density lipoprotein cholesterol \<1.03 mmol/L; current or previous smoker, defined as ≥5 cigarettes per day on average; significant renal dysfunction (estimated glomerular filtration rate ≥30 and \<60 mL/min per 1.73 m^2^ or urine albumin:creatinine ratio ≥30 mg albumin/g creatinine); or polyvascular disease (CHD and cerebrovascular disease or CHD and peripheral arterial disease). Darapladib did not influence the risk of major adverse cardiac events (MACE).[10](#jah32465-bib-0010){ref-type="ref"}, [11](#jah32465-bib-0011){ref-type="ref"} More detailed descriptions of the study design and population were published previously.[10](#jah32465-bib-0010){ref-type="ref"}, [11](#jah32465-bib-0011){ref-type="ref"}, [12](#jah32465-bib-0012){ref-type="ref"} All patients provided written informed consent, and the relevant ethics committees in each participating country approved the study, in accordance with the Helsinki Declaration.

Baseline Clinical Assessment and Questionnaire {#jah32465-sec-0012}
----------------------------------------------

At baseline, 15 528 participants (98%) completed a lifestyle questionnaire. This included the following question: "Overall, how do you feel your general health is now?" Possible responses were *excellent, very good, good, average*, and *poor*. Because only a small proportion of participants responded with excellent and poor, results are presented for 3 groups (1) excellent or very good, (2) good, and (3) average or poor.

In addition to the cardiovascular risk criteria needed for study inclusion, the following information was recorded at baseline: age, sex, diagnosis of hypertension, history of congestive heart failure, prior myocardial infarction, prior percutaneous coronary intervention or coronary artery bypass grafting, and New York Heart Association functional class. Body mass index was calculated in kg/m^2^. Geographic regions of enrollment were North America, South America including Mexico, Western Europe including Australia and New Zealand, Eastern Europe and Asia including South Africa. These country groupings were chosen primarily by geographic location but also considered the similarity of race, culture, and gross domestic product of countries.

On the lifestyle questionnaire, patients indicated whether they lived alone and the number of years of education completed, classified as *\<8 years, 8 to 12 years, trade school*, or *college or university*. Financial stress and home‐ and work‐related stress were graded as *never or rarely, sometimes, often*, or *always*. Depressive symptoms were assessed from the questions "How is your current mood?" (denoted as "depressed mood") and "Have you lost interest in activities or hobbies that normally give you pleasure?" (denoted as "loss of interest"), with possible responses of *never or rarely, sometimes, often*, or *always*.[13](#jah32465-bib-0013){ref-type="ref"} Physical activity was assessed from the total hours of moderate‐intensity (4 metabolic equivalents) and vigorous‐intensity (8 metabolic equivalents) physical activity during an average week.[14](#jah32465-bib-0014){ref-type="ref"}, [15](#jah32465-bib-0015){ref-type="ref"} A healthy diet was classified using a Mediterranean diet score based on responses to a simple food‐frequency questionnaire.[16](#jah32465-bib-0016){ref-type="ref"} The number of remaining teeth was recorded. Tooth loss was classified as ≤25 teeth.[17](#jah32465-bib-0017){ref-type="ref"}

Hemoglobin, white blood cell count, creatinine, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, trigylcerides, and C‐reactive protein were measured at a Quest Diagnostics Clinical Laboratory. In addition, blood samples were obtained from 14 577 patients at baseline and stored until biochemical analysis. Lipoprotein‐associated phospholipase A~2~ was measured at diaDexus Inc. High‐sensitivity troponin T, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), cystatin C, interleukin 6, and growth differentiation factor 15 were measured by an electrochemiluminescence immunoassay using a Cobas e 601 analyzer (Roche Diagnostics) at the Uppsala Clinical Research Center Laboratory in Uppsala, Sweden.

Clinical Outcomes {#jah32465-sec-0013}
-----------------

The primary end point of MACE was the composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points were total mortality, cardiovascular mortality, noncardiovascular mortality, myocardial infarction, stroke, major coronary events, and hospital admission for heart failure. Clinical outcomes were adjudicated by a committee. The event definitions and main results of the study were presented elsewhere.[10](#jah32465-bib-0010){ref-type="ref"}, [11](#jah32465-bib-0011){ref-type="ref"} The median follow‐up time was 3.7 years (interquartile range: 3.5--3.8 years). Vital status was complete for 99.3% of patients and 99.6% of total possible follow‐up time.

Statistical Analysis {#jah32465-sec-0014}
--------------------

The baseline characteristics were summarized, with categorical variables presented as count and proportion and continuous variables presented as mean and standard deviation. To investigate differences across the 3 groups of patients, the categorical variables were compared with the χ^2^ test. Continuous variables were compared with Mann--Whitney nonparametric tests.

To investigate the associations between different covariates and self‐reported health, multivariable ordinal logistic regressions were used due to the ordinal nature of the dependent variable (excellent or very good, good, average or poor). The results of the regression analyses are presented as adjusted odds ratios (ORs) and 95% confidence intervals. The ORs describe the associations of different covariates with decreasing levels of self‐reported health. Standardized ORs are presented for all continuous variables. All biomarkers were based on a 1‐SD increase, ORs for body mass index and Mediterranean diet score were based on a 1‐U increase, and ORs for physical activity (metabolic equivalent in hours per week) is based on a 50% increase. To evaluate the relative strength of association of different covariates with self‐reported health, χ^2^−*df* was plotted.[18](#jah32465-bib-0018){ref-type="ref"} This statistic allows comparison of predictors with different parameters, with a higher number indicating a stronger association.

Associations between self‐reported health and the study outcomes were assessed using Cox proportional hazards regression models and expressed with hazard ratio and 95% confidence interval. The underlying proportional hazards assumptions of the Cox proportional hazards models were verified by Schoenfeld residual tests. Using a multivariate model, we adjusted for demographic variables (age at randomization, sex, geographic region), psychosocial measures (depressed mood, loss of interest in hobbies, financial stress, stress at work or home, years of education), lifestyle risk factors (body mass index, smoking status, physical activity,[15](#jah32465-bib-0015){ref-type="ref"} Mediterranean diet score,[16](#jah32465-bib-0016){ref-type="ref"} attendance at cardiac rehabilitation), disease markers at baseline (diagnosis of hypertension, congestive heart failure, significant renal dysfunction, prior myocardial infarction, prior coronary revascularization \[percutaneous coronary intervention or coronary artery bypass grafting\]), prior multivessel chronic heart disease, diabetes mellitus, polyvascular disease, tooth loss, New York Heart Association functional class), and biomarkers (low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, hemoglobin, high‐sensitivity troponin T, interleukin 6, growth differentiation factor 15, triglycerides, estimated glomerular filtration rate \[using the Chronic Kidney Disease Epidemiology Collaboration formula\], creatinine, white blood cell count, high‐sensitivity C‐reactive protein, NT‐proBNP, cystatin C, and lipoprotein‐associated phospholipase A~2~ activity). The covariates included in the model were prespecified based on previous analyses from the STABILITY trial.[16](#jah32465-bib-0016){ref-type="ref"}, [17](#jah32465-bib-0017){ref-type="ref"}, [19](#jah32465-bib-0019){ref-type="ref"}, [20](#jah32465-bib-0020){ref-type="ref"} Kaplan--Meier curves were constructed for MACE by self‐reported health groups.

All analyses were performed using SAS software version 9.4 (SAS Institute). For all statistical analyses, a 2‐sided *P*\<0.05 was considered statistically significant.

Results {#jah32465-sec-0015}
=======

The baseline characteristics of the study population are presented for participants reporting excellent or very good, good, and average or poor self‐reported health in Table [1](#jah32465-tbl-0001){ref-type="table-wrap"}. A broad range of demographic, geographic, psychosocial, lifestyle‐related, and conventional cardiovascular risk factors, disease markers, and biomarkers were associated with self‐reported health. Thirty‐two of these 38 covariates were associated with self‐reported health in univariate analysis, with *P*\<0.0001.

###### 

Demographic and Baseline Characteristics by Self‐Reported General Health Levels

                                               Excellent or Very Good (n=2304)   Good (n=6863)     Average or Poor (n=6361)   Total (N=15 528)   Odds Ratio for one category decrease in health OR (95% CI)   *P* Value
  -------------------------------------------- --------------------------------- ----------------- -------------------------- ------------------ ------------------------------------------------------------ -------------------------------------------------
  Demographics                                                                                                                                                                                                
  Age, y                                                                                                                                                                                                      
  Mean (SD)                                    65.2 (8.9)                        64.7 (9.3)        63.7 (9.5)                 64.4 (9.3)         0.88 (0.85--0.91)                                            \<0.0001[§](#jah32465-note-0006){ref-type="fn"}
  Sex                                                                                                                                                                                                         
  Female                                       294 (12.8)                        1228 (17.9)       1378 (21.7)                2900 (18.7)        1.44 (1.34--1.56)                                            \<0.0001
  Race                                                                                                                                                                                                        
  Black                                        40 (1.7)                          157 (2.3)         164 (2.6)                  361 (2.3)          1.40 (1.15--1.71)                                            \<0.0001
  Central, South, or Southeast Asian           104 (4.5)                         531 (7.7)         528 (8.3)                  1163 (7.5)         1.45 (1.30--1.63)                                            
  East Asian or Japanese                       150 (6.5)                         421 (6.1)         951 (15.0)                 1522 (9.8)         2.59 (2.33--2.88)                                            
  Other                                        53 (2.3)                          168 (2.4)         112 (1.8)                  333 (2.1)          0.89 (0.72--1.09)                                            
  White                                        1957 (84.9)                       5586 (81.4)       4606 (72.4)                12 149 (78.2)      Reference group                                              
  Geographic region                                                                                                                                                                                           
  Asia/Pacific                                 234 (10.2)                        890 (13.0)        1429 (22.5)                2553 (16.4)        3.37 (3.05--3.71)                                            \<0.0001
  Eastern Europe                               177 (7.7)                         1436 (20.9)       1849 (29.1)                3462 (22.3)        3.30 (3.02--3.61)                                            
  South America                                217 (9.4)                         662 (9.6)         440 (6.9)                  1319 (8.5)         1.40 (1.25--1.58)                                            
  Western Europe                               737 (32.0)                        2071 (30.2)       1546 (24.3)                4354 (28.0)        1.48 (1.36--1.60)                                            
  North America                                939 (40.8)                        1804 (26.3)       1097 (17.2)                3840 (24.7)        Reference group                                              
  Psychosocial measures                                                                                                                                                                                       
  Depressed mood                                                                                                                                                                                              
  Often/always                                 100 (4.4)                         524 (7.9)         1148 (18.7)                1772 (11.7)        4.25 (3.82--4.74)                                            \<0.0001
  Sometimes                                    820 (36.1)                        3000 (45.0)       3023 (49.2)                6843 (45.4)        1.84 (1.73--1.97)                                            
  Never/rarely                                 1354 (59.5)                       3142 (47.1)       1976 (32.1)                6472 (42.9)        Reference group                                              
  Loss of interest                                                                                                                                                                                            
  Often/always                                 84 (3.7)                          508 (7.6)         1107 (18.1)                1699 (11.3)        4.09 (3.67--4.55)                                            \<0.0001
  Sometimes                                    472 (20.8)                        1979 (29.7)       2236 (36.6)                4687 (31.2)        2.00 (1.87--2.15)                                            
  Never/rarely                                 1715 (75.5)                       4174 (62.7)       2768 (45.3)                8657 (57.5)        Reference group                                              
  Financial stress                                                                                                                                                                                            
  Often/always                                 205 (9.1)                         895 (13.4)        1386 (22.6)                2486 (16.5)        2.44 (2.23--2.67)                                            \<0.0001
  Sometimes                                    633 (28.0)                        2165 (32.5)       2114 (34.5)                4912 (32.6)        1.47 (1.38--1.57)                                            
  Never/rarely                                 1424 (63.0)                       3603 (54.1)       2630 (42.9)                7657 (50.9)        Reference group                                              
  Lives alone                                                                                                                                                                                                 
  Yes                                          302 (13.2)                        897 (13.1)        862 (13.6)                 2061 (13.3)        1.03 (0.95--1.13)                                            0.4556
  No                                           1991 (86.8)                       5941 (86.9)       5480 (86.4)                13 412 (86.7)      Reference group                                              
  Stress at work or at home                                                                                                                                                                                   
  Often/always                                 312 (13.8)                        1156 (17.3)       1513 (24.6)                2981 (19.8)        1.96 (1.80--2.14)                                            \<0.0001
  Sometimes                                    1027 (45.4)                       3126 (46.8)       2898 (47.2)                7051 (46.7)        1.33 (1.24--1.43)                                            
  Never/rarely                                 925 (40.9)                        2400 (35.9)       1732 (28.2)                5057 (33.5)        Reference group                                              
  Years of education                                                                                                                                                                                          
  9--12 y                                      710 (30.9)                        2125 (31.1)       1897 (30.0)                4732 (30.6)        0.75 (0.69--0.82)                                            \<0.0001
  College/university                           858 (37.3)                        1923 (28.2)       1572 (24.9)                4353 (28.2)        0.60 (0.55--0.66)                                            
  Trade school                                 347 (15.1)                        1262 (18.5)       1205 (19.1)                2814 (18.2)        0.87 (0.79--0.95)                                            
  \<8 y                                        384 (16.7)                        1513 (22.2)       1651 (26.1)                3548 (23.0)        Reference group                                              
  Lifestyle risk factors                                                                                                                                                                                      
  Body mass index, kg/m^2^                                                                                                                                                                                    
  Mean (SD)                                    28.5 (4.4)                        28.9 (4.8)        29.2 (5.4)                 28.9 (5.0)         1.09 (1.01--1.02)                                            \<0.0001[‡](#jah32465-note-0006){ref-type="fn"}
  Smoking status                                                                                                                                                                                              
  Current smoker                               269 (11.7)                        1172 (17.1)       1362 (21.4)                2803 (18.1)        1.44 (1.32--1.58)                                            \<0.0001
  Former smoker                                1298 (56.3)                       3589 (52.3)       3060 (48.1)                7947 (51.2)        0.92 (0.86--0.99)                                            
  Never smoked                                 737 (32.0)                        2102 (30.6)       1939 (30.5)                4778 (30.8)        Reference group                                              
  Mediterranean diet score                                                                                                                                                                                    
  Mean (SD)                                    12.8 (3.1)                        12.0 (3.0)        11.7 (3.1)                 12.0 (3.1)         0.93 (0.92--0.94)                                            \<0.0001[‡](#jah32465-note-0006){ref-type="fn"}
  Physical activity (MET h/wk)                                                                                                                                                                                
  Mean (SD)                                    60.7 (50.6)                       55.2 (49.7)       46.8 (45.6)                52.6 (48.5)        0.90 (0.89--0.92)                                            \<0.0001[¶](#jah32465-note-0006){ref-type="fn"}
  Attended cardiac rehabilitation                                                                                                                                                                             
  Yes                                          966 (42.0)                        2409 (35.3)       2037 (32.3)                5412 (35.1)        0.781 (0.734--0.831)                                         \<0.0001
  Disease markers                                                                                                                                                                                             
  Diagnosis of hypertension                                                                                                                                                                                   
  Yes                                          1512 (65.6)                       4841 (70.5)       4759 (74.8)                11 112 (71.6)      1.34 (1.25--1.43)                                            \<0.0001
  Congestive heart failure at baseline                                                                                                                                                                        
  Yes                                          223 (9.7)                         1255 (18.3)       1857 (29.2)                3335 (21.5)        2.24 (2.08--2.41)                                            \<0.0001
  Significant renal dysfunction                                                                                                                                                                               
  Yes                                          581 (25.2%)                       2011 (29.3%)      2094 (32.9%)               4686 (30.2%)       1.27 (1.19--1.35)                                            \<0.0001
  Prior myocardial infarction                                                                                                                                                                                 
  Yes                                          1288 (55.9)                       4069 (59.3)       3784 (59.5)                9141 (58.9)        1.07 (1.01--1.14)                                            0.0226
  Prior coronary revasculation (PCI or CABG)                                                                                                                                                                  
  Yes                                          1852 (80.4)                       5222 (76.1)       4574 (71.9)                11 648 (75.0)      0.74 (0.70--0.80)                                            \<0.0001
  Prior multivessel chronic heart disease                                                                                                                                                                     
  Yes                                          266 (11.5)                        988 (14.4)        1084 (17.0)                2338 (15.1)        1.32 (1.22--1.44)                                            \<0.0001
  Diabetes mellitus                                                                                                                                                                                           
  Yes                                          677 (29.4)                        2537 (37.0)       2801 (44.0)                6015 (38.7)        1.50 (1.41--1.60)                                            \<0.0001
  Polyvascular disease                                                                                                                                                                                        
  Yes                                          235 (10.2)                        999 (14.6)        1101 (17.3)                2335 (15.0)        1.40 (1.30--1.53)                                            \<0.0001
  Tooth loss                                                                                                                                                                                                  
  ≤25 teeth                                    1593 (69.4)                       5294 (77.9)       5193 (82.6)                12 080 (78.5)      1.61 (1.50--1.73)                                            \<0.0001
  26--32 (all)                                 701 (30.6)                        1505 (22.1)       1093 (17.4)                3299 (21.5)        Reference group                                              
  NYHA functional class                                                                                                                                                                                       
  Class II, III, or IV                         120 (5.2)                         856 (12.5)        1467 (23.1)                2443 (15.7)        2.63 (2.42--2.87)                                            \<0.0001
  Medications at randomization                                                                                                                                                                                
  Aspirin                                                                                                                                                                                                     
  Yes                                          2181 (94.7)                       6385 (93.0)       5779 (90.9)                14 345 (92.4)      0.687 (0.613--0.770)                                         \<0.0001
  ACEI or ARB                                                                                                                                                                                                 
  Yes                                          1632 (70.8)                       5291 (77.1)       5036 (79.2)                11 959 (77.0)      1.301 (1.212--1.396)                                         \<0.0001
  Statin                                                                                                                                                                                                      
  Yes                                          2243 (97.4)                       6689 (97.5)       6174 (97.1)                15 106 (97.3)      0.892 (0.743--1.071)                                         0.2213
  Beta blocker                                                                                                                                                                                                
  Yes                                          1728 (75.0)                       5413 (78.9)       5117 (80.4)                12 258 (78.9)      1.206 (1.122--1.297)                                         \<0.0001
  P2Y~12~ inhibitor                                                                                                                                                                                           
  Yes                                          718 (31.2)                        2214 (32.3)       2319 (36.5)                5251 (33.8)        1.203 (1.129--1.281)                                         \<0.0001
  Biomarkers                                                                                                                                                                                                  
  LDL‐C, mmol/L                                                                                                                                                                                               
  Mean (SD)                                    2.1 (0.8)                         2.2 (0.8)         2.3 (0.9)                  2.2 (0.9)          1.18 (1.14--1.21)                                            \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  HDL‐C, mmol/L                                                                                                                                                                                               
  Mean (SD)                                    1.3 (0.3)                         1.2 (0.3)         1.2 (0.3)                  1.2 (0.3)          0.88 (0.86--0.91)                                            \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  Hemoglobin, g/L                                                                                                                                                                                             
  Mean (SD)                                    144.5 (12.3)                      142.7 (13.8)      141.8 (14.7)               142.6 (14.0)       0.89 (0.87--0.92)                                            \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  High‐sensitivity troponin T, ng/L                                                                                                                                                                           
  Mean (SD)                                    10.8 (9.3)                        11.9 (12.2)       13.7 (23.2)                12.4 (17.2)        1.19 (1.14--1.25)                                            \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  Interleukin 6, ng/L                                                                                                                                                                                         
  Mean (SD)                                    2.4 (2.0)                         2.8 (2.9)         3.1 (3.2)                  2.8 (2.9)          1.18 (1.14--1.22)                                            \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  GDF‐15, ng/L                                                                                                                                                                                                
  Mean (SD)                                    1415.2 (974.0)                    1532.0 (1081.4)   1669.5 (1302.6)            1569.2 (1164.0)    1.17 (1.13--1.21)                                            \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  Triglycerides, mmol/L                                                                                                                                                                                       
  Mean (SD)                                    1.6 (1.0)                         1.8 (1.2)         1.9 (1.5)                  1.8 (1.3)          1.17 (1.13--1.21)                                            \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  eGFR (CKD‐EPI), mL/min/1.73 m^2^                                                                                                                                                                            
  Mean (SD)                                    73.9 (16.3)                       73.3 (17.1)       73.8 (18.2)                73.6 (17.4)        1.01 (0.98--1.04)                                            0.4384[∥](#jah32465-note-0006){ref-type="fn"}
  Creatinine                                                                                                                                                                                                  
  Mean (SD)                                    93.5 (19.4)                       94.1 (24.1)       93.7 (23.7)                93.9 (23.3)        1.00 (0.97--1.03)                                            0.8168[∥](#jah32465-note-0006){ref-type="fn"}
  White blood cell count (1×10^9^/L)                                                                                                                                                                          
  Mean (SD)                                    6.4 (1.7)                         6.8 (1.9)         7.0 (1.9)                  6.8 (1.9)          1.19 (1.156--1.232)                                          \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  hs‐CRP, mg/L                                                                                                                                                                                                
  Mean (SD)                                    2.4 (6.6)                         2.8 (5.9)         3.4 (7.2)                  3.0 (6.6)          1.12 (1.08--1.16)                                            \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  NT‐proBNP, ng/L                                                                                                                                                                                             
  Mean (SD)                                    267.6 (490.9)                     345.4 (636.3)     431.9 (989.6)              368.2 (783.1)      1.21 (1.16--1.26)                                            \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  Cystatin C, ng/L                                                                                                                                                                                            
  Mean (SD)                                    1.0 (0.3)                         1.0 (0.3)         1.1 (0.3)                  1.1 (0.3)          1.13 (1.10--1.17)                                            \<0.0001[∥](#jah32465-note-0006){ref-type="fn"}
  Lp‐PLA~2~ activity, μmol/min/L                                                                                                                                                                              
  Mean (SD)                                    173.6 (44.4)                      175.4 (47.2)      176.5 (50.0)               175.6 (47.9)       1.04 (1.01--1.07)                                            0.0177[∥](#jah32465-note-0006){ref-type="fn"}

Values are mean (SD) and n (%) for categorical variables. Percentages refer to the percentage of patients in each level of self‐reported health and of all patients who have the given characteristic. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; CI, confidence interval; CKD‐EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; GDF‐15, growth differentiation factor‐15; HDL‐C, high‐density lipoprotein cholesterol; hs‐CRP, high‐sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; LpPLA~2~, lipoprotein‐associated phospholipase A~2~; MET, metabolic equivalent; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; OR, odds ratio; PCI, percutaneous coronary intervention.

OR for 1‐category decrease in self‐reported health category: ^‡^OR based on 1‐U increase, ^§^OR based on 10‐U increase, ^∥^OR based on 1‐SD increase, ^¶^OR based on 50% increase.

Patients who self‐reported poorer health were slightly more likely to be on an angiotensin‐converting enzyme inhibitor or angiotensin II receptor antagonist, a beta‐blocker, or a P2Y~12~ antagonist compared with those with better self‐reported health (Table [1](#jah32465-tbl-0001){ref-type="table-wrap"}). Aspirin use was slightly less in patients reporting poorer general health. Statin use was similar by self‐reported health. There was no difference in self‐reported health at baseline according to allocation to darapladib or placebo, as expected by randomization.

Variables independently associated with self‐reported health in a multivariable adjusted model are displayed in Table [2](#jah32465-tbl-0002){ref-type="table-wrap"}. The statistical strength of associations between different variables and self‐reported health is compared in Figure [1](#jah32465-fig-0001){ref-type="fig"}. The strongest independent associations were with geographic region, depressed mood, and low physical activity. The geographic region with the best self‐reported health was North America, followed by South America, Western Europe, Eastern Europe, and Asia (Table [1](#jah32465-tbl-0001){ref-type="table-wrap"}). After adjusting for other covariates associated with self‐reported health, persons from South America and North America had the best self‐reported health, participants from Western Europe reported slightly worse general health, and those from Eastern Europe and Asia were much more likely to report poorer health (Table [2](#jah32465-tbl-0002){ref-type="table-wrap"}). A less healthy diet, obesity, smoking, diabetes mellitus, hypertension, exertional dyspnea, cardiovascular disease markers, and tooth loss were each associated with poorer self‐reported health. Blood markers independently associated with poorer self‐reported health were high‐sensitivity cardiac troponin T, growth differentiation factor 15, interleukin 6, low‐density lipoprotein cholesterol, and low hemoglobin. Age and sex were not associated with self‐reported health in the fully adjusted model. Attendance at cardiac rehabilitation was not associated with self‐reported health after adjusting for covariates (Table [2](#jah32465-tbl-0002){ref-type="table-wrap"}).

###### 

Covariates Independently Associated With Self‐Reported Health in a Model Adjusting for All Other Covariates

  Variables                                        Contrast                                  OR (95% CI)                                                    Overall *P* Value
  ------------------------------------------------ ----------------------------------------- -------------------------------------------------------------- -------------------
  Demographics                                                                                                                                              
  Age at randomization, y                                                                    1.080 (1.006--1.159)[†](#jah32465-note-0008){ref-type="fn"}    0.0330
  Sex                                              Female vs male                            1.175 (0.989--1.395)                                           0.0664
   Geographic region                               Asia/Pacific vs North America             4.795 (4.142--5.549)                                           \<0.0001
  Eastern Europe vs North America                  3.015 (2.651--3.427)                                                                                     
  South America vs North America                   0.866 (0.732--1.025)                                                                                     
  Western Europe vs North America                  1.647 (1.477--1.837)                                                                                     
  Psychosocial measures                                                                                                                                     
   Depressed mood                                  Often/always vs never/rarely              2.214 (1.897--2.583)                                           \<0.0001
  Sometimes vs never/rarely                        1.408 (1.292--1.535)                                                                                     
   Lost interest in hobbies                        Often/always vs never/rarely              2.625 (2.270--3.036)                                           \<0.0001
  Sometimes vs never/rarely                        1.502 (1.378--1.638)                                                                                     
   Financial stress                                Often/always vs never/rarely              1.455 (1.287--1.645)                                           \<0.0001
  Sometimes vs never/rarely                        1.150 (1.054--1.255)                                                                                     
  Lives alone                                      Yes vs no                                 1.009 (0.905--1.126)                                           0.8676
   Stress at work or at home                       Often/always vs never/rarely              1.222 (1.081--1.382)                                           0.0024
  Sometimes vs never/rarely                        1.136 (1.040--1.242)                                                                                     
   Years of education                              9--12 vs \<8 y                            0.873 (0.783--0.974)                                           \<0.0001
  Trade school vs \<8 y                            0.968 (0.856--1.094)                                                                                     
  College/university vs \<8 y                      0.785 (0.700--0.881)                                                                                     
  Lifestyle risk factors                                                                                                                                    
  Body mass index, kg/m^2^                                                                   1.028 (1.019--1.037)[\*](#jah32465-note-0008){ref-type="fn"}   \<0.0001
  Smoking status                                   Current smoker vs never/former smoker     1.285 (1.153--1.432)                                           \<0.0001
  Mediterranean diet score                                                                   0.959 (0.947--0.972)[\*](#jah32465-note-0008){ref-type="fn"}   \<0.0001
  Physical activity, MET h/wk                                                                0.916 (0.901--0.931)[§](#jah32465-note-0008){ref-type="fn"}    \<0.0001
  Cardiac rehabilitation                           Yes vs no                                 0.962 (0.888--1.043)                                           0.3514
  Disease markers                                                                                                                                           
  Diagnosis of hypertension                        Yes vs no                                 1.285 (1.181--1.399)                                           \<0.0001
  Congestive heart failure at baseline             Yes vs no                                 1.141 (1.001--1.301)                                           0.0481
  Significant renal dysfunction                    Yes vs no                                 1.061 (0.965--1.165)                                           0.2194
  Prior myocardial infarction                      Yes vs no                                 0.895 (0.825--0.971)                                           0.0076
  Prior coronary revascularization (PCI or CABG)   Yes vs no                                 0.876 (0.797--0.962)                                           0.0055
  Prior multivessel chronic heart disease          Yes vs no                                 1.228 (1.098--1.372)                                           0.0003
  Diabetes mellitus                                Yes vs no                                 1.229 (1.128--1.338)                                           \<0.0001
  Polyvascular disease                             Yes vs no                                 1.272 (1.144--1.415)                                           \<0.0001
  Tooth loss                                       ≤25 vs 26--32 (all) teeth                 1.387 (1.262--1.524)                                           \<0.0001
  NYHA functional class                            Class II,III, or IV vs no class/class I   1.554 (1.337--1.806)                                           \<0.0001
  Biomarkers                                                                                                                                                
  LDL‐C, mmol/L                                                                              1.092 (1.040--1.146)[‡](#jah32465-note-0008){ref-type="fn"}    0.0004
  HDL‐C, mmol/L                                                                              0.939 (0.898--0.982)[‡](#jah32465-note-0008){ref-type="fn"}    0.0062
  Hemoglobin, g/L                                                                            0.951 (0.909--0.995)[‡](#jah32465-note-0008){ref-type="fn"}    0.0307
  High‐sensitivity troponin T, ng/L                                                          1.081 (1.026--1.140)[‡](#jah32465-note-0008){ref-type="fn"}    0.0036
  Interleukin 6, ng/L                                                                        1.070 (1.023--1.119)[‡](#jah32465-note-0008){ref-type="fn"}    0.0033
  GDF‐15, ng/L                                                                               1.070 (1.017--1.124)[‡](#jah32465-note-0008){ref-type="fn"}    0.0083
  Triglycerides, mmol/L                                                                      1.050 (0.995--1.109)[‡](#jah32465-note-0008){ref-type="fn"}    0.0767
  eGFR (CKD‐EPI), mL/min/1.73 m^2^                                                           1.117 (0.971--1.286)[‡](#jah32465-note-0008){ref-type="fn"}    0.1219
  Creatinine                                                                                 1.131 (0.979--1.307)[‡](#jah32465-note-0008){ref-type="fn"}    0.0949
  White blood cell count (1×10^9^/L)                                                         0.988 (0.949--1.028)[‡](#jah32465-note-0008){ref-type="fn"}    0.5541
  High‐sensitivity C‐reactive protein, mg/L                                                  1.009 (0.967--1.053)[‡](#jah32465-note-0008){ref-type="fn"}    0.6678
  NT‐proBNP, ng/L                                                                            1.049 (0.995--1.105)[‡](#jah32465-note-0008){ref-type="fn"}    0.0750
  Cystatin C, ng/L                                                                           0.943 (0.885--1.006)[‡](#jah32465-note-0008){ref-type="fn"}    0.0750
  Lp‐PLA~2~ activity, μmol/min/L                                                             0.965 (0.918--1.013)[‡](#jah32465-note-0008){ref-type="fn"}    0.1506

CABG indicates coronary artery bypass grafting; CI, confidence interval; CKD‐EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; GDF‐15, growth differentiation factor‐15; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; LpPLA~2~, lipoprotein‐associated phospholipase A~2~; MET, metabolic equivalent; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; OR, odds ratio; PCI, percutaneous coronary intervention.

OR for 1‐category decrease in self‐reported health category: \*OR based on 1‐U increase, ^†^OR based on 10‐U increase, ^‡^OR based on 1‐SD increase, ^§^OR based on 50% increase.

![Relative strength of association with self‐reported health of each variable included in the full model, as measured by the Wald χ^2^ test minus the predictor degrees of freedom: (χ^2^−*df*)=χ^2^−predictor *df*. Higher values on the *x*‐axis indicate a stronger association with self‐reported health. hs indicates high sensitivity; MET, metabolic equivalent; NYHA, New York Heart Association.](JAH3-6-e006096-g001){#jah32465-fig-0001}

There was a stepwise increase in the risk of MACE with worsening self‐reported health (Figure [2](#jah32465-fig-0002){ref-type="fig"}). The hazard ratios for adverse outcomes by self‐reported health before and after adjustment for covariables are displayed in Figure [3](#jah32465-fig-0003){ref-type="fig"}A and [3](#jah32465-fig-0003){ref-type="fig"}B, respectively. Poorer self‐reported health was associated with increased cardiovascular and total mortality, myocardial infarction, stroke, and hospital admission for heart failure (Figure [3](#jah32465-fig-0003){ref-type="fig"}A). After adjustment for all covariates, these associations were maintained for all outcomes except heart failure hospitalization and stroke (Figure [3](#jah32465-fig-0003){ref-type="fig"}B).

![Kaplan--Meier plot of major adverse cardiovascular events by self‐reported health at baseline.](JAH3-6-e006096-g002){#jah32465-fig-0002}

![Adverse events by self‐reported health at baseline adjusted (A) for treatment allocation only and (B) for all covariates. Hazard ratios (HRs) and 95% confidence intervals (CIs) are presented for each outcome for patients reporting good and average or poor health compared with the reference group that reported very good or excellent health. *Heart failure* refers to hospitalization for heart failure. CV indicates cardiovsacular; MACE, major adverse cardiac events; MI, myocardial infarction.](JAH3-6-e006096-g003){#jah32465-fig-0003}

Discussion {#jah32465-sec-0016}
==========

In this study, which evaluated a global population of patients with stable CHD on optimal secondary prevention treatment, average or poor self‐reported health was independently associated with a 2‐ to 3‐fold increased risk of cardiovascular mortality and myocardial infarction compared with patients reporting very good or excellent health. These observations indicate that self‐reported health is an important incremental risk indicator of myocardial infarction and cardiovascular mortality in patients with stable CHD, despite optimal secondary prevention treatment. The association with a large number of prognostically important variables is consistent with the conclusion that self‐reported health is a global health measure that both reflects the cumulative effects of a broad range of known risk indicators and indicates the importance of additional risk indicators not measurable by conventional methods.

A number of large studies have evaluated associations between self‐reported health and mortality in general populations.[4](#jah32465-bib-0004){ref-type="ref"}, [6](#jah32465-bib-0006){ref-type="ref"}, [21](#jah32465-bib-0021){ref-type="ref"} In the UK Biobank cohort, which included nearly 500 000 volunteers and evaluated multiple clinical, biomarker, and genetic risk factors, self‐reported health was the strongest single predictor of all‐cause mortality in men and the third strongest mortality predictor in women after a cancer diagnosis and illness or injury.[4](#jah32465-bib-0004){ref-type="ref"} Meta‐analyses of smaller studies have also been consistent in reporting associations between poorer self‐reported health and cardiovascular and all‐cause mortality.[5](#jah32465-bib-0005){ref-type="ref"}, [22](#jah32465-bib-0022){ref-type="ref"} In a large Swedish general population cohort, poorer self‐reported health was associated with a higher prevalance of multiple cardiovascular risk factors, and with an increased risk of myocardial infarction during follow‐up over ≈13 years.[21](#jah32465-bib-0021){ref-type="ref"}

A systematic review of studies reporting the relationship between self‐reported health and fatal and nonfatal cardiovascular outcomes[22](#jah32465-bib-0022){ref-type="ref"} identified 3 studies[8](#jah32465-bib-0008){ref-type="ref"}, [9](#jah32465-bib-0009){ref-type="ref"}, [23](#jah32465-bib-0023){ref-type="ref"} including 10 648 patients with known cardiovascular or ischemic heart disease. In this meta‐analysis, patients with poor health compared with good or excellent health had a ≈2.4 times higher risk of cardiovascular death, consistent with the current study. However these studies have limitations, including poor measurement of baseline risk factors and cardiovascular disease status, lack of detail on study methods, and poor ascertainment of disease status or severity.

Most previous studies reporting self‐reported health have been undertaken in a single country. In the current study, which included patients from 39 countries and multiple regions of the world, self‐reported health was strongly associated with geographic region and country of residence. These observations suggest that cultural or regional norms need to be considered when interpreting self‐reported health. In addition, the large geographic differences in self‐reported health changed after adjustment for covariates, suggesting that geographic differences in self‐reported health reflect both differences in the burden of disease or symptoms and different perceptions of their impact on health. Socioeconomic[24](#jah32465-bib-0024){ref-type="ref"} and international gradients[25](#jah32465-bib-0025){ref-type="ref"} in adverse outcomes for patients with CHD persist despite adjustment for conventional cardiovascular risk factors and are well described. It is possible these could be explained in part by differences in general health.

Both psychosocial and conventional cardiovascular risk factors have been associated with self‐reported health in previous studies.[7](#jah32465-bib-0007){ref-type="ref"}, [21](#jah32465-bib-0021){ref-type="ref"}, [22](#jah32465-bib-0022){ref-type="ref"} In these studies, however, information on multiple covariates was more limited, and a detailed analysis of the relative importance of different factors was not undertaken. In the current study, depressive symptoms were strongly associated with self‐reported health, consistent with an effect of mood on the perception of health and the impact of poorer health on mood. Stress from various causes and fewer years of education were also associated with poorer self‐reported health. Other indicators of socioeconomic status were not assessed in this study. Lifestyle risk factors, including current smoking, physical activity, diet, and body weight, were relatively strong predictors of self‐reported health.

The presence of clinical markers of cardiovascular disease or risk, including prior myocardial infarction, stroke, polyvascular disease, diabetes mellitus, and renal dysfunction, was associated with poorer self‐reported health; however, the strength of these associations, as assessed by the χ^2^ statistic, was generally less than that of psychosocial and lifestyle measures. Associations between self‐reported health and blood biomarkers, some of which are powerful risk predictors, were generally weaker than those of clinical variables. Associations of self‐reported health with low‐density lipoprotein cholesterol, hemoglobin, interleukin 6, growth differentiation factor 15, and troponin T are consistent with an influence of multiple pathophysiological pathways.

There were modest differences in use of several evidence‐based medications by self‐reported health, but the reasons for these differences cannot be determined reliably in this observational study. Differences in medication use could be explained by treatment indication, such as impaired left ventricular function, which is a stronger indication for beta blockers and angiotensin‐converting enzyme inhibitors or angiotensin receptor antagonists, or effects of treatment on general health (eg, if beta blockers caused fatigue). A common association between medication use and other factors that influence health, such as socioeconomic conditions, geography, or medical care, is also possible.[12](#jah32465-bib-0012){ref-type="ref"}

Study Limitations {#jah32465-sec-0017}
-----------------

The current study has a number of limitations. The degree to which the observed associations are causal cannot be established in this observational study. Despite the availability of a wide array of clinical and biochemical risk indicators and risk factors, there are still additional unmeasured risk factors, for example, details on all comorbidities, extent of coronary lesions, and genetic factors that were not included in the database. Furthermore, participants selected to participate in a clinical trial may not be representative of all CHD patients; however, the large geographically and culturally diverse study population and the internal consistency of the data suggest that results are likely to be broadly applicable. Additional strengths of the current analysis include the standardized assessment of multiple clinical, psychosocial, and lifestyle variables and near‐complete ascertainment of outcomes.

This study described associations between self‐reported health and a broad range of prognostically important variables. Our observation that many of these associations remained statistically significant after multivariable adjustment indicates that self‐reported health captures a broad range of conditions affecting sense of well‐being.

Broad geographic regions were prespecified for the analysis, but chosen groupings are relatively crude indicators of the importance of cultural, medical, and socioeconomic differences between and within countries---a limitation that is likely to diminish estimates of the importance of geographic factors. Despite this, geographic region was a strong independent predictor of both self‐reported health and MACE.

Study Implications {#jah32465-sec-0018}
------------------

An assessment of self‐reported health can be undertaken simply as part of almost any consultation. Poor or worsening self‐reported health may occur for many reasons, both cardiac and noncardiac. This study suggests that poorer general health, whatever the reason, is associated with a higher risk of MACE in patients with stable CHD. This raises the possibility that interventions that improve overall health could reduce cardiovascular risk.

Disease‐specific patient‐centered outcome measures, such as the Quality of Life After Myocardial Infarction Questionnaire[26](#jah32465-bib-0026){ref-type="ref"} or the Seattle Angina Questionnaire,[27](#jah32465-bib-0027){ref-type="ref"} may be more sensitive to the impact of cardiovascular disease on quality of life than on overall health.[1](#jah32465-bib-0001){ref-type="ref"} Self‐reported overall health is influenced by many factors. Compared with disease‐specific tools, general health may be less sensitive to changes in symptoms directly related to, for example, CHD. Nevertheless, disease‐specific measures have some disadvantages. They generally include more questions, are less comparable for patients with different medical problems, are more time consuming to administer, and may not capture the impact of non--disease‐related factors on general health.

Because self‐reported overall health is a powerful risk marker, considering it could better inform decisions about treatment or delivery of health care and discussions about risks to future health. Few studies have evaluated whether and how response to different treatments relates to self‐reported health. Further research is needed to evaluate the effectiveness of targeting health care based on assessment of self‐reported general health.

Conclusions {#jah32465-sec-0019}
===========

In a global stable CHD population, self‐reported health was strongly associated with geographical region, psychosocial variables, and lifestyle risk factors. Self‐reported health was independently associated with MACE when adjusting for baseline characteristics including a wide array of prognostic biomarkers. These data support the conclusion that self‐perceived health and psychosocial and lifestyle‐related factors contribute to cardiovascular events beyond what is measurable by established risk indicators.
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**Appendix S1.** STABILITY Trial---Organizational.
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Click here for additional data file.

[^1]: The STABILITY Investigators are listed in Appendix [S1](#jah32465-sup-0001){ref-type="supplementary-material"}, which is available at <http://jaha.ahajournals.org/content/6/8/e006096/DC1/embed/inline-supplementary-material-1.pdf>
